| 2.05 -0.09 (-4.21%) | 12-15 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.55 | 1-year : | 2.98 |
| Resists | First : | 2.19 | Second : | 2.55 |
| Pivot price | 1.92  |
|||
| Supports | First : | 1.76 | Second : | 1.5 |
| MAs | MA(5) : | 1.99 |
MA(20) : | 1.83 |
| MA(100) : | 1.68 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 83.8 |
D(3) : | 83.1 |
| RSI | RSI(14): 56.4  |
|||
| 52-week | High : | 2.46 | Low : | 0.85 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ABOS ] has closed below upper band by 17.5%. Bollinger Bands are 25.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.15 - 2.16 | 2.16 - 2.17 |
| Low: | 1.95 - 1.97 | 1.97 - 1.98 |
| Close: | 2.03 - 2.05 | 2.05 - 2.07 |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Fri, 28 Nov 2025
Acumen Pharmaceuticals And 2 Other Penny Stocks Worth Watching - simplywall.st
Tue, 18 Nov 2025
ABOS: B of A Securities Lowers Price Target But Maintains Buy Ra - GuruFocus
Tue, 18 Nov 2025
B of A Securities Maintains Acumen Pharmaceuticals (ABOS) Buy Recommendation - Nasdaq
Mon, 17 Nov 2025
Acumen Pharmaceuticals begins open-label extension for Alzheimer’s drug - Investing.com
Mon, 17 Nov 2025
Acumen Pharmaceuticals (NASDAQ: ABOS) doses first patient in Phase 2, 52-week OLE - Stock Titan
Thu, 13 Nov 2025
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2025 Earnings Call Transcript - Insider Monkey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 61 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 7 (%) |
| Held by Institutions | 64.7 (%) |
| Shares Short | 575 (K) |
| Shares Short P.Month | 1,370 (K) |
| EPS | -2.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.54 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -42.3 % |
| Return on Equity (ttm) | -86 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.97 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -124 (M) |
| Levered Free Cash Flow | -79 (M) |
| PE Ratio | -0.93 |
| PEG Ratio | 0 |
| Price to Book value | 1.32 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|